Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
November 28, 2023 08:00 ET
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023 09:15 ET
|
Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Florida Cancer Specialists & Research Institute Presents Clinical Research Results at 2022 ASCO® Annual Meeting
June 03, 2022 09:57 ET
|
Florida Cancer Specialists & Research Institute
Fort Myers, Florida, June 03, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLS (FCS) physicians are presenting the outcomes of 33 clinical trials, the majority being...
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2022 16:45 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Provectus Biopharmaceuticals Announces Oral Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Checkpoint-Refractory Advanced Cutaneous Melanoma at Melanoma Bridge 2020
December 07, 2020 07:00 ET
|
Provectus Biopharmaceuticals Inc.
29% ORR (7% CR) and 57% DCR (RECIST 1.1)75% ORR in anti-PD-1-refractory patients56% DCR (11% CR) in patients refractory to anti-CTLA-4 and anti-PD-1 combination therapyPresentation delivered by...
uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting
November 30, 2020 07:05 ET
|
uniQure Inc.
~ Strong Presence at ASH Featuring Five Presentations, Including Late-BreakingOral Presentation on HOPE-B Pivotal Trial ~ ~ uniQure to Host Investor Webcast Tuesday, December 8, 2020 at 5:00 p.m. ET...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020
November 12, 2020 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing Phase 1b/2 study of autolytic cancer immunotherapy PV-10, an injectable...
Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020
August 26, 2020 18:05 ET
|
Genmab A/S
Media Release Copenhagen, Denmark, Aug 27, 2020 InnovaTV 204 study evaluated tisotumab vedotin in recurrent or metastatic cervical cancer Data from the study selected as a late-breaking abstract at...
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
December 05, 2015 17:00 ET
|
Achillion Pharmaceuticals, Inc.
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology Detailing Novel Results With Factor D Inhibitors
November 05, 2015 09:03 ET
|
Achillion Pharmaceuticals, Inc.
- Highly potent, specific, and oral factor D inhibitors effectively block hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) cells and mitigate the accumulation of C3 fragments – -...